Changes in Hong Kong stocks | Cinda Biotech (01801) rose nearly 3% at the end of the session. The company will submit a marketing application for a new drug using Maxidopeptide 9mg for adult weight control

The Zhitong Finance App learned that Cinda Biotech (01801) rose nearly 3% at the end of the session. As of press release, it had risen 2.62% to HK$92, with a turnover of HK$747 million.

According to the news, on November 20, Cinda Biotech announced that the Phase III clinical study (GLORY-2) of IBI362 injection () in moderately and severely obese people in China has reached the main end point and all key secondary endpoints. Cinda Biotech will submit a marketing application for the regulatory authorities in the near future as a new drug for adult weight control.

According to public information, Maxidol is a glucagon (GCG) /glucagon-like peptide-1 (GLP-1) dual agonist jointly promoted by Cinda Biotech and Lilly Pharmaceuticals. It is also the world's first approved GCG/GLP-1 dual agonist. The drug has been approved in China for two indications, which are used for long-term weight control in adult obese or overweight patients and blood sugar control for adult type 2 diabetics.